AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies

AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies

Bibliografiske detaljer
Main Authors:	Lachowiez, C, Borthakur, G, Loghavi, S, Zeng, Z, Kadia, T, Masarova, L, Takahashi, K, Tippett, G, Garcia, J, Bose, P, Jabbour, E, Ravandi, F, Daver, N, Manero, GG, Vyas, P, Kantarjian, H, Konopleva, M, DiNardo, C
Format:	Conference item
Sprog:	English
Udgivet:	Elsevier 2022

Lignende værker

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
af: Lachowiez, CA, et al.
Udgivet: (2022)

A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies
af: Lachowiez, CA, et al.
Udgivet: (2021)

A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies
af: Lachowiez, CA, et al.
Udgivet: (2023)

Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
af: DiNardo, C, et al.
Udgivet: (2019)

Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia
af: DiNardo, CD, et al.
Udgivet: (2020)

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
af: DiNardo, CD, et al.
Udgivet: (2021)

AML-262 Pivekimab Sunirine (PVEK, IMGN632) triplet with azacitidine and venetoclax shows broad activity in adverse genetic subsets of relapsed/refractory acute myeloid leukemia and reduced infusion-related reactions
af: Daver, N, et al.
Udgivet: (2022)

Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase ib results
af: Daver, NG, et al.
Udgivet: (2023)

A phase 3, randomized trial of magrolimab in combination with venetoclax and azacitidine in previously untreated patients with acute myeloid leukemia ineligible for intensive chemotherapy (ENHANCE-3)
af: Daver, N, et al.
Udgivet: (2022)

A phase 1B/2 study of the CD123-targeting antibody-drug conjugate pivekimab sunirine (IMGN632) in combination with venetoclax (VEN) and azacitidine (AZA) for patients with CD123-positive AML
af: Daver, NG, et al.
Udgivet: (2022)

Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)
af: DiNardo, CD, et al.
Udgivet: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
af: Garcia-Manero, G, et al.
Udgivet: (2021)

Molecular features associated with response to enasidenib plus azacitidine in newly diagnosed IDH2-mutated acute myeloid leukemia
af: Risueño, A, et al.
Udgivet: (2023)

Mechanisms of response and resistance to AML therapies
af: Stoilova, B, et al.
Udgivet: (2020)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
af: Garcia-Manero, G, et al.
Udgivet: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
af: Garcia-Manero, G, et al.
Udgivet: (2021)

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
af: Risueño, A, et al.
Udgivet: (2024)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
af: Garcia-Manero, G, et al.
Udgivet: (2021)

The first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results
af: Sallman, D, et al.
Udgivet: (2021)

Outcomes of relapsed/refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: results from the NCRI AML trials
af: Hills, R, et al.
Udgivet: (2018)

Azacitidine prolongs overall survival in older patients with Acute Myeloid Leukemia (AML) with poor prognostic karyotypes
af: Doehner, H, et al.
Udgivet: (2017)

AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results
af: Daver, N, et al.
Udgivet: (2022)

AML-432 Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, Phase 3 IDHENTIFY Trial
af: DiNardo, CD, et al.
Udgivet: (2022)

Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the randomized, phase 3 IDHentify Trial
af: DiNardo, CD, et al.
Udgivet: (2021)

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
af: Goodyear, O, et al.
Udgivet: (2012)

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results
af: Daver, NG, et al.
Udgivet: (2022)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
af: de Botton, S, et al.
Udgivet: (2022)

TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions
af: Daver, NG, et al.
Udgivet: (2022)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma.
af: Krell, D, et al.
Udgivet: (2011)

Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study
af: Sallman, DA, et al.
Udgivet: (2023)

Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR)
af: Doehner, H, et al.
Udgivet: (2016)

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
af: Stein, EM, et al.
Udgivet: (2017)

Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations
af: Emir, U, et al.
Udgivet: (2015)

Real-world effectiveness of azacitidine in treatment-naive patients with higher-risk myelodysplastic syndromes
af: Rajakumaraswamy, N, et al.
Udgivet: (2023)

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
af: Rahmani, NE, et al.
Udgivet: (2021)

IDH1: Linking metabolism and epigenetics
af: Raineri, S, et al.
Udgivet: (2018)

AMW 348 - PERUNCITAN MAC 05.
af: PPP, Pusat Pengajian Pengurusan
Udgivet: (2005)

JTP 348 - PERUNCITAN MAC 05.
af: PPJJ, Pusat Pengajian Jarak Jauh
Udgivet: (2005)

AMW348 – PERUNCITAN MAC 05.
af: PPP, Pusat Pengajian Pengurusan
Udgivet: (2005)

AML-399 A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia (AML)
af: Vyas, P, et al.
Udgivet: (2022)